Genfit S.A.

Paris Stock Exchange GNFT.PA

Genfit S.A. Receivables for the year ending December 31, 2023: USD 36.10 M

Genfit S.A. Receivables is USD 36.10 M for the year ending December 31, 2023, a 112.12% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Genfit S.A. Receivables for the year ending December 31, 2022 was USD 17.02 M, a 106.61% change year over year.
Genfit S.A. Receivables for the year ending December 31, 2021 was USD 8.24 M, a -43.43% change year over year.
Genfit S.A. Receivables for the year ending December 31, 2020 was USD 14.56 M, a 7.81% change year over year.
Genfit S.A. Receivables for the year ending December 31, 2019 was USD 13.50 M, a 49,066.86% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Paris Stock Exchange: GNFT.PA

Genfit S.A.

CEO	Mr. M. Pascal Prigent
IPO Date	Dec. 19, 2006
Location	France
Headquarters	Parc EurasantE
Employees	169
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Key trends

Past 5 years